Tsveta Milenkova

2.6k total citations
32 papers, 1.5k citations indexed

About

Tsveta Milenkova is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Tsveta Milenkova has authored 32 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Genetics. Recurrent topics in Tsveta Milenkova's work include PARP inhibition in cancer therapy (17 papers), BRCA gene mutations in cancer (11 papers) and Ovarian cancer diagnosis and treatment (11 papers). Tsveta Milenkova is often cited by papers focused on PARP inhibition in cancer therapy (17 papers), BRCA gene mutations in cancer (11 papers) and Ovarian cancer diagnosis and treatment (11 papers). Tsveta Milenkova collaborates with scholars based in United Kingdom, United States and Italy. Tsveta Milenkova's co-authors include Tudor–Eliade Ciuleanu, Manuel Cobo, Alan Webster, Gyula Ostoros, R. McCormack, Jean‐Yves Douillard, Jill Walker, Simon Dearden, Rose McCormack and Rebecca Cole and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Tsveta Milenkova

31 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tsveta Milenkova United Kingdom 15 1.0k 906 546 467 243 32 1.5k
Jacqui Rowbottom United Kingdom 10 1.2k 1.2× 791 0.9× 321 0.6× 567 1.2× 271 1.1× 14 1.6k
Gregory Friberg United States 18 722 0.7× 318 0.4× 269 0.5× 504 1.1× 144 0.6× 35 1.2k
Véronique D’Hondt France 21 781 0.8× 335 0.4× 241 0.4× 298 0.6× 276 1.1× 83 1.3k
Iván Díaz-Padilla United States 21 728 0.7× 273 0.3× 392 0.7× 634 1.4× 260 1.1× 53 1.4k
Georgiana Kuhlmann United States 5 753 0.7× 920 1.0× 357 0.7× 500 1.1× 57 0.2× 6 1.3k
Federico Piacentini Italy 23 1.3k 1.3× 517 0.6× 718 1.3× 386 0.8× 49 0.2× 115 1.9k
Ernesto Wasserman United States 17 812 0.8× 358 0.4× 377 0.7× 418 0.9× 36 0.1× 35 1.2k
Débora De Melo Gagliato Brazil 14 953 0.9× 528 0.6× 501 0.9× 426 0.9× 39 0.2× 36 1.5k
Glenwood D. Goss Canada 20 541 0.5× 327 0.4× 396 0.7× 526 1.1× 53 0.2× 39 1.2k
Kim A. Reiss United States 19 971 1.0× 226 0.2× 444 0.8× 452 1.0× 47 0.2× 63 1.4k

Countries citing papers authored by Tsveta Milenkova

Since Specialization
Citations

This map shows the geographic impact of Tsveta Milenkova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsveta Milenkova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsveta Milenkova more than expected).

Fields of papers citing papers by Tsveta Milenkova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsveta Milenkova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsveta Milenkova. The network helps show where Tsveta Milenkova may publish in the future.

Co-authorship network of co-authors of Tsveta Milenkova

This figure shows the co-authorship network connecting the top 25 collaborators of Tsveta Milenkova. A scholar is included among the top collaborators of Tsveta Milenkova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsveta Milenkova. Tsveta Milenkova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cecchi, Franco, Marlon C. Rebelatto, Norah J. Shire, et al.. (2023). The HORIZON III retrospective exploratory analysis: HER2 expression amplification in colorectal cancer.. Journal of Clinical Oncology. 41(4_suppl). 194–194. 1 indexed citations
3.
Lee, Jung‐Min, Richard G. Moore, Sharad Ghamande, et al.. (2022). Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. Clinical Cancer Research. 28(19). 4186–4193. 33 indexed citations
4.
Herzog, Thomas J., Ignace Vergote, Leonard G. Gomella, et al.. (2022). Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. European Journal of Cancer. 179. 136–146. 23 indexed citations
5.
6.
Friedländer, Michael, Sarah J. Lord, Rebecca Asher, et al.. (2021). Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer. 154. 190–200. 9 indexed citations
7.
Hodgson, Darren, Jessica Brown, Simon Dearden, et al.. (2021). Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. Gynecologic Oncology. 163(3). 563–568. 10 indexed citations
8.
Penson, Richard T., Ricardo Villalobos-Valencia, David Cibula, et al.. (2019). Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.. Journal of Clinical Oncology. 37(15_suppl). 5506–5506. 22 indexed citations
9.
10.
Liu, Joyce F., Jungmin Lee, Ellie S. Strock, et al.. (2018). Technology Applications: Use of Digital Health Technology to Enable Drug Development. JCO Clinical Cancer Informatics. 2(2). 1–12. 14 indexed citations
11.
Zhou, Diansong, Jianguo Li, Khanh Bui, et al.. (2018). Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clinical Pharmacokinetics. 58(5). 615–625. 25 indexed citations
12.
Timms, Kirsten M., Jessica Brown, Darren Hodgson, et al.. (2018). Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.. Journal of Clinical Oncology. 36(15_suppl). 5563–5563. 3 indexed citations
13.
Douillard, Jean‐Yves, Gyula Ostoros, Manuel Cobo, et al.. (2014). Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology. 9(9). 1345–1353. 348 indexed citations
14.
Ostoros, Gyula, Manuel Cobo, Tudor–Eliade Ciuleanu, et al.. (2013). First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. British Journal of Cancer. 110(1). 55–62. 322 indexed citations
15.
16.
Boer, Richard H. De, Óscar Arrieta, James Chih‐Hsin Yang, et al.. (2011). Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 29(8). 1067–1074. 230 indexed citations
17.
Blackhall, Fiona, Mary O’Brien, Peter Schmid, et al.. (2010). A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(8). 1285–1288. 34 indexed citations
18.
19.
Boer, R. de, Yves Humblet, Juergen Wolf, et al.. (2008). An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Annals of Oncology. 20(3). 486–491. 26 indexed citations
20.
Vansteenkiste, Johan, Yves Humblet, Lucia Nogová, et al.. (2007). Vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer (NSCLC): An open-label, multicenter phase I study. Journal of Clinical Oncology. 25(18_suppl). 7654–7654. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqui Rowbottom Breakdown of academic impact, for papers by Gregory Friberg Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Iván Díaz-Padilla Breakdown of academic impact, for papers by Georgiana Kuhlmann Breakdown of academic impact, for papers by Federico Piacentini Breakdown of academic impact, for papers by Ernesto Wasserman Breakdown of academic impact, for papers by Débora De Melo Gagliato Breakdown of academic impact, for papers by Glenwood D. Goss Breakdown of academic impact, for papers by Kim A. Reiss
Rankless by CCL
2026